Narla Venkata, Blaha Michael J, Blumenthal Roger S, Michos Erin D
The Ciccarone Preventive Cardiology Center, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Vasc Health Risk Manag. 2009;5:1033-42. doi: 10.2147/vhrm.s6412. Epub 2009 Dec 29.
Statins have emerged at the forefront of preventive cardiology and have significantly reduced cardiovascular events and mortality. Nonetheless, cardiovascular disease remains the leading cause of death in the United States and in other developed countries, as well as the etiology of significant morbidity and health-care expenditure. In an attempt to reduce potentially missed opportunities for instituting preventive therapy, the JUPITER study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) and the AURORA study (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) examined the effect of statins in two specific patient populations who currently do not meet the guidelines for statin treatment, but nonetheless, are at high cardiovascular risk. This review outlines the JUPITER and AURORA trials, interprets the data and significance of the results, analyses the drawbacks and impact of both trials and delineates the potential for further clinical trials.
他汀类药物已成为预防心脏病学的前沿药物，并显著降低了心血管事件和死亡率。尽管如此，心血管疾病仍是美国和其他发达国家的主要死因，也是导致严重发病和医疗保健支出的病因。为了减少实施预防性治疗时可能错过的机会，JUPITER研究（他汀类药物在预防中的应用理由：评估瑞舒伐他汀的干预试验）和AURORA研究（评估瑞舒伐他汀在定期血液透析患者中的应用：生存和心血管事件评估）考察了他汀类药物对目前不符合他汀类治疗指南但心血管风险较高的两个特定患者群体的影响。本综述概述了JUPITER和AURORA试验，解释了结果的数据和意义，分析了两项试验的缺点和影响，并描述了进一步开展临床试验的可能性。
